Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma
Status:
Completed
Trial end date:
2016-12-29
Target enrollment:
Participant gender:
Summary
The purpose of this phase 1/2, open-label study was to evaluate the effect of oral
formulation of Ixazomib when added to standard melphalan and prednisone (MP) treatment. Both
phases of the study included participants who had newly diagnosed multiple myeloma and were
ineligible for high-dose therapy plus stem cell transplantation because of age (≥65 years of
age) or coexisting conditions and for whom standard MP treatment was indicated.